Haleon PLC Sponsored ADR (NYSE:HLN) Receives $13.40 Consensus Price Target from Analysts

Haleon PLC Sponsored ADR (NYSE:HLN) has been given a consensus rating of “Moderate Buy” by the eight brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, three have given a buy recommendation and two have given a strong buy recommendation to the company.

HLN has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of Haleon in a research report on Thursday, April 30th. Argus raised shares of Haleon to a “strong-buy” rating in a research report on Tuesday, March 17th. Finally, Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research report on Saturday, March 21st.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Parkside Financial Bank & Trust lifted its position in Haleon by 101.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock valued at $29,000 after buying an additional 1,433 shares during the last quarter. Western Wealth Management LLC acquired a new position in Haleon in the first quarter valued at about $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its position in Haleon by 402.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock valued at $30,000 after buying an additional 2,404 shares during the last quarter. Atlantic Union Bankshares Corp lifted its position in Haleon by 293.7% in the third quarter. Atlantic Union Bankshares Corp now owns 3,697 shares of the company’s stock valued at $33,000 after buying an additional 2,758 shares during the last quarter. Finally, Stance Capital LLC acquired a new position in Haleon in the third quarter valued at about $34,000. Institutional investors and hedge funds own 6.67% of the company’s stock.

Haleon Trading Down 1.5%

Shares of HLN stock opened at $9.08 on Tuesday. The company’s 50-day moving average price is $9.53 and its 200-day moving average price is $9.96. The company has a current ratio of 0.92, a quick ratio of 0.71 and a debt-to-equity ratio of 0.47. The stock has a market cap of $40.24 billion, a price-to-earnings ratio of 23.27, a PEG ratio of 2.06 and a beta of 0.15. Haleon has a twelve month low of $8.71 and a twelve month high of $11.42.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Saturday, February 14th. The company reported $6.32 earnings per share for the quarter. The firm had revenue of $3.65 billion for the quarter. As a group, equities analysts predict that Haleon will post 0.56 earnings per share for the current year.

Haleon Company Profile

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.